Analyst Price Targets — REPL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 11:49 am | — | Piper Sandler | $14.00 | $7.00 | TheFly | Replimune price target raised to $14 from $13 at Piper Sandler |
| November 3, 2025 9:23 am | Evan Seigerman | BMO Capital | $11.00 | $9.73 | TheFly | Replimune upgraded to Market Perform from Underperform at BMO Capital |
| October 27, 2025 10:17 am | — | H.C. Wainwright | $12.00 | $8.80 | TheFly | Replimune upgraded to Buy from Neutral at H.C. Wainwright |
| October 20, 2025 1:05 pm | — | Wedbush | $18.00 | $9.15 | TheFly | Wedbush upgrades Replimune to Outperform amid second BLA review |
| January 22, 2025 2:41 pm | Evan Seigerman | BMO Capital | $27.00 | $13.09 | TheFly | Replimune price target raised to $27 from $18 at BMO Capital |
| December 3, 2024 8:58 pm | Roger Song | Jefferies | $19.00 | $14.48 | StreetInsider | Replimune Group (REPL) PT Raised to $19 at Jefferies |
| June 7, 2024 6:07 am | Robert Burns | H.C. Wainwright | $17.00 | $7.11 | TheFly | Replimune Group price target raised to $17 from $12 at H.C. Wainwright |
| June 4, 2024 9:51 am | Peter Lawson | Barclays | $13.00 | $5.37 | StreetInsider | Barclays Reiterates Overweight Rating on Replimune Group (REPL) |
| May 17, 2024 7:40 am | Evan Seigerman | BMO Capital | $14.00 | $6.85 | StreetInsider | BMO Capital Reiterates Outperform Rating on Replimune Group (REPL) |
| December 12, 2022 7:42 am | — | BMO Capital | $70.00 | $25.00 | Benzinga | BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70 |
Latest News for REPL
The mean of analysts' price targets for Replimune Group (REPL) points to a 79.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Leerink Partners 2026 Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat…
The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update.
SG Americas Securities LLC grew its position in Replimune Group, Inc. (NASDAQ: REPL) by 868.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 98,731 shares of the company's stock after buying an additional 88,532 shares during the period. SG Americas Securities LLC owned approximately 0.13%
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for REPL.
U.S. House Trading
No House trades found for REPL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.